REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments

Regenxbio (RGNX) Reports Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS IINovember 7, 2018 5:27 PM Regenxbio (RGNX) Misses Q3 EPS by 12c, Revenues MissNovember 7, 2018 5:08 PM REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 VectorNovember 5, 2018 7:00 AM